Chemical Abstracts Service Registry Number: 53581-53-6 Formal Names: 4-Bromo-2,5-Dimethoxyamphetamine Informal Names: Bob, Bromo-DMA, Bromo-STP, PBR Type: Hallucinogen. See page 25 Federal Schedule Listing: Schedule I (DEA no. 7391) USA Availability: Illegal to possess Pregnancy Category: None
Uses. This drug became available in the 1960s. It can produce hallucinations and affect interpretations of time and space. Some persons who thought they took LSD were actually on DOB. Research has found DOB effects to develop more gradually and to be more prolonged than those of LSD.
A chemist who knew he was taking pure DOB reported that a small dose brightened his perception of colors and created a mellow mood. Larger doses created muscle tremors and increased insight into psychological issues. The chemist recommended against attempting to drive a car while intoxicated. In a controlled experimental setting with volunteers interested in using the drug to gain better awareness of themselves, the drug stimulated thoughts, feelings, and physical senses. People became more articulate, saw new meaning in ordinary experiences, and became more inclined to self-examination. In contrast to MDA experiences, the DOB volunteers showed less lethargy and were more interested in what was going on around them. No hallucinations occurred.
Drawbacks. In canines DOB can elevate body temperature and blood pressure. In humans DOB's physical effects can include nausea, diarrhea, muscle spasms, blood vessel spasms, sensations of tingling and burning, impaired sense of touch, convulsions, and seizures. The drug may be safe from a technical pharmaceutical standpoint because there is a huge difference between the size of a therapeutic dose and a lethal one, but the drug is so potent that small doses are known to kill. Effects may last for hours and suddenly intensify and become fatal. Characteristics of overdose can resemble those of amphetamine, including fear and physical aggression. The medical literature includes a DOB case somewhat resembling ergotism (see ergot), resulting in the patient's lower legs being amputated.
Abuse factors. Not enough scientific information to report.
Drug interactions. Alcohol may increase the strength of a DOB dose.
Cancer. Not enough scientific information to report.
Pregnancy. Not enough scientific information to report.
Additional scientific information may be found in:
Buhrich, N., G. Morris, and G. Cook. "Bromo-DMA: The Australasian Hallucinogen?" Australian and New Zealand Journal of Psychiatry 17 (1983): 275-79.
Davis, W.M. "LSD or DOB?" American Journal of Psychiatry 139 (1982): 1649.
Delliou, D. "4-Bromo-2,5-Dimethoxyamphetamine: Psychoactivity, Toxic Effects and Analytical Methods." Forensic Science International 21 (1983): 259-67.
Shulgin, A.T., T. Sargent, and C. Naranjo. "4-Bromo-2,5-Dimethoxyphenylisopropylam-ine, a New Centrally Active Amphetamine Analog." Pharmacology 5 (1971): 103-7.
Toennes, S.W., et al. "Aufklarung eines unklaren neurologischen Syndroms durch toxikologische Untersuchungen [Explanation of an Unclear Neurological Syndrome by Toxicologic Investigation]." Deutsche Medizinische Wochenschrift 125 (2000): 900-902. (Abstract in English).
Was this article helpful?